Influence of vector dose on factor IX-specific T and B cell responses in muscle-directed gene therapy

Human Gene Therapy

Volumn 13, Issue 11, 2002, Pages 1281-1291

  Herzog, Roland W ^a   Fields, Paul A ^a   Arruda, Valder R ^a   Brubaker, Jeff O ^b   Armstrong, Elina ^a   McClintock, Darryl ^c   Bellinger, Dwight A ^c   Couto, Linda B ^d   Nichols, Timothy C ^c   High, Katherine A ^a  

^a HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

^b WISTAR INSTITUTE   (United States)

^c UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^d Avigen Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; BLOOD CLOTTING FACTOR 9; DRUG CARRIER; IMMUNOGLOBULIN G; NEUTRALIZING ANTIBODY; VIRUS DNA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY PRODUCTION; ANTIGEN PRESENTATION; ARTICLE; B LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; CORRELATION ANALYSIS; DOG; DOSE RESPONSE; GENE THERAPY; HEMOPHILIA B; IMMUNOGLOBULIN PRODUCTION; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; LYMPHOCYTE PROLIFERATION; NONHUMAN; PROTEIN EXPRESSION; T LYMPHOCYTE;

ANIMALS; ANTIBODIES; B-LYMPHOCYTES; CELLS, CULTURED; CYTOKINES; DEPENDOVIRUS; DISEASE MODELS, ANIMAL; DOGS; FACTOR IX; GENE EXPRESSION; GENE THERAPY; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; HEMOPHILIA B; IMMUNOGLOBULIN G; INJECTIONS, INTRAMUSCULAR; LEUKOCYTES, MONONUCLEAR; LYMPHOCYTES; MITOGENS; MUSCLE, SKELETAL; T-LYMPHOCYTES; TIME FACTORS; TRANSGENES;

ADENO-ASSOCIATED VIRUS; ADENOVIRIDAE; ANIMALIA; CANIS FAMILIARIS;

EID: 0036376642     PISSN: 10430342     EISSN: None     Source Type: Journal    
DOI: 10.1089/104303402760128513     Document Type: Article

References (25)

1. Post-translational modifications or recombinant myotube-synthesized human factor IX
2. Non-Th2 regulatory T-cell control of Th1 autoimmunity
3. Canine hemophilia B resulting from a point mutation with unusual consequences
4. Choice of vector determines T cell subsets involved in immune responses against the secreted transgene product factor IX
5. Risk and prevention of anti-factor IX formation in AAV-mediated gene transfer in context of a large factor IX gene deletion
6. Recombinant adeno-associated virus for muscle directed gene therapy
7. The molecular basis of hemophilia A and B
8. + T cells
9. Stable gene transfer and expression of human blood coagulation factor IX after intramuscular injection of recombinant adeno-associated virus
10. Long-term correction of canine hemophilia B by gene transfer of blood coagulation factor IX mediated by adeno-associated viral vector
11. Absence of circulating factor IX antigen in hemophilia B dogs of the UNC-Chapel Hill colony
12. Muscle-directed gene transfer and transient immune suppression result in sustained partial correction of canine hemophilia B caused by a null mutation
13. Gene transfer as an approach to treating hemophilia
14. The incidence of factor VIII inhibitors in patients with severe hemophilia A
15. Evidence for gene transfer and expression of factor IX in haemophilia B patients treated with an AAV vector
16. A coagulation factor IX-deficient mouse model for human hemophilia B
17. Adeno-associated virus vectors can be efficiently produced without helper virus
18. A deletion mutation causes hemophilia B in Lhasa Apso dogs
19. Sustained phenotypic correction of hemophilia B dogs with a factor IX null mutation by liver-directed gene therapy
20. AAV-mediated gene transfer of human blood coagulation factor IX into mouse liver
21. Successful interference with cellular immune responses to immunogenic proteins encoded by recombinant viral vectors
22. Persistent and therapeutic concentrations of human factor IX in mice after hepatic gene transfer of recombinant AAV vectors
23. Correction of hemophilia B in canine and murine models using recombinant adeno-associated viral vectors
24. Sustained expression of therapeutic level of factor IX in hemophilia B dogs by AAV-mediated gene therapy in liver
25. Efficient long-term gene transfer into muscle tissue of immunocompetent mice by adeno-associated virus vector